Lilly’s Zepbound Resolves Sleep Apnea in 52% of Patients
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
- Latest
- Trending
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
The Open Medical-LLM leaderboard offers valuable insights into AI-related medical devices, although none of the approved devices use generative AI.
A lawsuit is underway as the misuse of #ivermectin as a COVID treatment continues. The article discusses the legal ramifications ...
Stock and bond markets will be closed on Good Friday. Get expert advice straight to your e-mail for profitable opportunities. ...
The FDA will now allow yogurt makers to claim that their products may prevent Type 2 diabetes, based on limited ...
Cagent Vascular's series C financing round has raised over $30m, enabling them to expand their product portfolio and accelerate US ...
Incannex Healthcare makes breakthrough in smoking cessation drug program as FDA approves clinical trials for CannQuit-N chewing gum.
A Louisiana woman files lawsuit against Amazon and pharmaceutical companies over contaminated eye drops leading to severe injuries. Consumer trust ...
Merrimack Pharmaceuticals is set to dissolve after receiving a $225 million payment for FDA approval. Shareholders will receive a dividend ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.